Core Advantages of RenDu Bio HBV DNA Fully Automated High-Sensitivity Quantitative Assay
【High-Sensitivity Quantification・Meeting Guideline Requirements】
Detection sensitivity: 10 IU/mL, fulfilling HBV clinical guideline criteria.
【Fully Automated Process・Intelligent Analysis】
Integrated AutoSAT system enables full-process automation—
Sample in to result out, eliminating manual errors.
【High Efficiency・Rapid Reporting】
Direct loading of blood collection tubes (no transfer);
Results in 100 minutes, enhancing workflow efficiency.
【Random-Access Testing・Zero Reagent Waste】
Breaks traditional batch limitations; supports on-demand testing with no reagent waste.
【Dual-Calibration Quantification・Multi-Layer Assurance】
Internal & external calibration monitors entire detection process,
Eliminates inter-well variation for precise quantification.
One-Tube Dual Detection: DNA + RNA Dual-Target Viral Tracking
HBV DNA is mainly used to evaluate the replication level of hepatitis B virus, while HBV RNA reflects the transcriptional activity of intrahepatic cccDNA. The combined detection of both can break through the limitations of single indicators,
comprehensively evaluate the activity state of hepatitis B virus, cover the whole process of pre-treatment efficacy prediction, antiviral therapy efficacy monitoring, and post-treatment relapse risk assessment, providing a more comprehensive basis for precision diagnosis and treatment of hepatitis B.
RenduBio achieves HBV DNA+RNA "dual testing in one tube" through the AutoSAT fully automated nucleic acid analysis system. Blood collection tubes are directly loaded without transfer. Extraction, amplification, and result analysis are fully
automated. Double results are obtained with one click.
The launch of Rendu Bio’s HBV DNA fully automated high sensitivity detection reagent means hepatitis B has entered the era of DNA+RNA "dual testing in one tube." It avoids repeated blood draws for patients while providing more comprehensive personalized solutions from diagnosis, treatment to discontinuation management, contributing to the goal of "eliminating hepatitis B."
Currently, Rendu Bio has completed the product layout for "bloodborne infections," achieving full coverage of fully automated high sensitivity detection product lines for the three major infectious diseases "HBV, HCV, and HIV," and building a complete solution from confirmation to efficacy monitoring and patient management.
